by Bob Roehr
BIOBUSINESS	Institutional Review Boards in Crisis The watchdogs of research have had a massive increase in responsibility, but lack the support to do their job Email: Bob Roehr - broehr@the-scientist.com The Scientist 2005, 19(9):42 Published   9 May 2005

The pressure is building on Institutional Review Boards. Those venerable groups are charged with protecting patients in clinical trials, largely by providing ethical oversight and making sure informed consent guidelines are followed. However, the expanding size, complexity, and public visibility of clinical trials have strained Institutional Review Boards (IRBs), and are leading to a reevaluation of their role and function.

(continued >>)

To continue reading this full article, you must be a subscriber to The Scientist.

You are only a few minutes away from unlimited access.

If you already have an online subscription, please Log-In Now.
New to The Scientist? Register to get access to a selection of our content, interactive features and useful tools free without a subscription.

Subscribe to The Scientist to get unlimited access to our premium content

Get unlimited access to this article and over 20 years of The Scientist archives. You won’t miss a word – all for as little as $4.95.  Subscribe now.

The Scientist offers site licenses to institutions and organizations. Recommend us to your librarian and get online access through your place or work or study.